Cytokinetics Earnings Before Interest Taxes and Depreciation Amortization EBITDA Trend from 2010 to 2022

CYTK
 Stock
  

USD 50.30  0.83  1.68%   

Cytokinetics Earnings Before Interest Taxes and Depreciation Amortization EBITDA are decreasing with slightly volatile movements from year to year. Earnings Before Interest Taxes and Depreciation Amortization EBITDA are predicted to flatten to -201,771,632. For the period between 2010 and 2022, Cytokinetics, Earnings Before Interest Taxes and Depreciation Amortization EBITDA quarterly trend regression had mean deviation of 56,046,017 and r-value of (0.78). Cytokinetics Selling General and Administrative Expense is increasing as compared to previous years. The last year's value of Selling General and Administrative Expense was reported at 96.8 Million.
  
Check Cytokinetics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytokinetics main balance sheet or income statement drivers, such as Gross Profit of 59.3 M, Interest Expense of 17.7 M or Operating Expenses of 277 M, as well as many exotic indicators such as Interest Coverage of 7.48, Long Term Debt to Equity of 0.56 or PPandE Turnover of 1.67. Cytokinetics financial statements analysis is a perfect complement when working with Cytokinetics Valuation or Volatility modules. It can also supplement Cytokinetics' financial leverage analysis and stock options assessment as well as various Cytokinetics Technical models . Continue to the analysis of Cytokinetics Correlation against competitors.

Cytokinetics Quarterly Earnings Before Interest Taxes and Depreciation Amortization EBITDA

(15.61 Million)

Cytokinetics Earnings Before Interest Taxes and Depreciation Amortization EBITDA Breakdown

Showing smoothed Earnings Before Interest Taxes and Depreciation Amortization EBITDA of Cytokinetics with missing and latest data points interpolated. EBITDA is a non-GAAP accounting metric that is widely used when assessing the performance of companies; calculated by adding Depreciation Amortization and Accretion back to Earning Before Interest and Taxes EBIT.Cytokinetics' Earnings Before Interest Taxes and Depreciation Amortization EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cytokinetics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported (184.04 M)10 Years Trend
Decreasing
Slightly volatile
   Earnings Before Interest Taxes and Depreciation Amortization EBITDA   
Share
       Timeline  

Cytokinetics Earnings Before Interest Taxes and Depreciation Amortization EBITDA Regression Statistics

Arithmetic Mean(80,241,587)
Geometric Mean 61,584,900
Coefficient Of Variation(84.32)
Mean Deviation 56,046,017
Median(46,667,000)
Standard Deviation 67,657,557
Range 221,663,632
R-Value(0.78)
R-Squared 0.61
Significance 0.001729
Slope(13,520,235)

Cytokinetics Earnings Before Interest Taxes and Depreciation Amortization EBITDA History

2012-39.9 M
2013-33.3 M
2014-14.2 M
2015-36.6 M
201619.9 M
2017-122.9 M
2018-101.3 M
2019-113.8 M
2020-109.5 M
2021-196.6 M
2022-201.8 M

About Cytokinetics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Cytokinetics income statement, its balance sheet, and the statement of cash flows. Cytokinetics investors use historical funamental indicators, such as Cytokinetics's Earnings Before Interest Taxes and Depreciation Amortization EBITDA, to determine how well the company is positioned to perform in the future. Although Cytokinetics investors may use each financial statement separately, they are all related. The changes in Cytokinetics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cytokinetics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Cytokinetics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Cytokinetics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Earnings Before Interest Taxes and Depreciation Amortization EBITDA-196.6 M-201.8 M
Earnings before Tax-215.3 M-221 M
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Cytokinetics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Idea Optimizer Now

   

Idea Optimizer

Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
All  Next Launch Module

Pair Trading with Cytokinetics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytokinetics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytokinetics will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Cytokinetics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytokinetics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytokinetics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytokinetics to buy it.
The correlation of Cytokinetics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytokinetics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytokinetics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cytokinetics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to the analysis of Cytokinetics Correlation against competitors. Note that the Cytokinetics information on this page should be used as a complementary analysis to other Cytokinetics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Complementary Tools for Cytokinetics Stock analysis

When running Cytokinetics price analysis, check to measure Cytokinetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytokinetics is operating at the current time. Most of Cytokinetics' value examination focuses on studying past and present price action to predict the probability of Cytokinetics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cytokinetics' price. Additionally, you may evaluate how the addition of Cytokinetics to your portfolios can decrease your overall portfolio volatility.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Is Cytokinetics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
4.7 B
Quarterly Revenue Growth YOY
30.29
Return On Assets
-0.17
Return On Equity
-3.38
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cytokinetics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.